SCHEMBL24849280

SCHEMBL24849280

CCOC(C)n1cc(-c2ccn3nc(N)nc3c2)cn1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 14/20 0.45
PIK3CD O00329 11/20 0.45
JAK2 O60674 2/20 0.43
JAK1 P23458 2/20 0.43
TYK2 P29597 1/20 0.43
JAK3 P52333 1/20 0.43
MAP3K5 Q99683 3/20 0.40
PIK3CA P42336 2/20 0.40
PAK4 O96013 1/20 0.40
PIK3CB P42338 1/20 0.40
CSNK1A1 P48729 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40
CSNK1G1 Q9HCP0 1/20 0.40
CD274 Q9NZQ7 1/20 0.39
PIP5K1C O60331 1/20 0.36
PI4KA P42356 1/20 0.36
PI4KB Q9UBF8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23209322 0.87 JAK2 (0.43) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL25223046 0.84 JAK2 (0.45) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL25224447 0.84 JAK2 (0.44) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL25271218 0.81 JAK2 (0.40) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL23209295 0.81 JAK2 (0.42) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL25230751 0.79 JAK2 (0.42) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL23209368 0.78 JAK2 (0.44) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL24849259 0.78 JAK2 (0.41) PIK3CGPIK3CDJAK2JAK1TYK2
SCHEMBL12066115 0.77 JAK2 (0.57) JAK2JAK1TYK2JAK3
SCHEMBL23233918 0.77 JAK2 (0.41) PIK3CGPIK3CDJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-22 US disclosed
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-22 US disclosed
US-20230183250-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed
WO-2023107705-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-15 WO disclosed
WO-2023107705-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION (US) 2023-06-15 WO disclosed
US-20230183250-A1 BICYCLIC AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed
US-20230002376-A1 BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183250-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 PIK3CG 661/4885PIK3CD 567/4885JAK2 232/4885
US-20230002376-A1 BICYCLIC PYRAZOLYL AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 PIK3CG 549/4885PIK3CD 457/4885JAK2 181/4885
US-20230192706-A1 BICYCLIC AMINES AS CDK2 INHIBITORS CDK2, CCNI, CDK1 PIK3CG 661/4885PIK3CD 567/4885JAK2 232/4885
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS CDK12, CDK1, CDK2 PIK3CG 706/4885PIK3CD 734/4885JAK2 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.